Positive Scientific Review

Deltex Medical Group PLC
23 January 2008


                            Deltex Medical Group plc

           Positive scientific review of CardioQ technology published

23 January 2008 - Deltex Medical Group plc ('Deltex Medical'), the UK's leading
haemodynamic monitoring company, today announces the results of a new review of
the CardioQ(TM) technology of oesophageal Doppler monitoring (ODM).

The paper from doctors at the University of Auckland in New Zealand was
published in the journal Anaesthesia and assesses, using the technique of
meta-analysis, the clinical evidence for the use of ODM in abdominal surgery.
Meta-analysis (a systematic scientific review which considers related evidence
as a whole) is used heavily by doctors within clinical circles to determine
technologies and interventions which should be established as standards of care.

The meta-analysis concluded that 'Pooled analysis showed a reduced hospital stay
in the intervention group. Overall, there were fewer complications and ICU
admissions, and less requirement for inotropes (drugs used to enhance the
heart's performance) in the intervention group. Return of normal
gastro-intestinal function was also significantly faster in the intervention
group. Oesophageal Doppler use for monitoring and optimisation of flow-related
haemodynamic variables improves short-term outcome in patients undergoing major
abdominal surgery.'

The full article (S. M. Abbas, A. G. Hill (2008): Systematic review of the
literature for the use of oesophageal Doppler monitor for fluid replacement in
major abdominal surgery Anaesthesia 63 (1), 44-51) is available to subscribers
at http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2044.2007.05233.x

Deltex Medical's Chief Executive, Andy Hill commented:

'This is the first meta-analysis on ODM to have been published in a
peer-reviewed scientific journal. Its publication only reinforces that the
CardioQ is closer than ever before to being widely acknowledged as a standard of
care.'

For further information, please contact:-

Deltex Medical Group plc                     01243 774 837

Nigel Keen, Chairman                         [e-mail]
Andy Hill, Chief Executive                   [e-mail]
Ewan Phillips, Finance Director              [e-mail]

Gavin Anderson & Company                     0207 554 1400
Deborah Walter                               [e-mail]
Robert Speed                                 [e-mail]

Charles Stanley Securities                   020 7149 6000
(Nominated Adviser)
Philip Davies                                [e-mail]
Russell Cook                                 [e-mail]

Notes for Editors

Deltex Medical manufactures and markets the CardioQ(TM) monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already around 1,500 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange